Results 191 to 200 of about 31,381 (233)

Investigating the role of NEIL3 in colorectal cancer resistance to oxaliplatin

Colorectal cancer (CRC) is the third most common type of cancer and accounts for 8 % of cancer related deaths worldwide. While the likelihood of colorectal carcinogenesis increases with age, genetics and lifestyle are major predisposing factors. Treatment can be curative and promises a 39 – 65% survival rate depending on the stage at cancer diagnosis ...
openaire  

Mechanical forces inducing oxaliplatin resistance in pancreatic cancer can be targeted by autophagy inhibition. [PDF]

Commun Biol
Kalli M, Mpekris F, Charalambous A, Michael C, Stylianou C, Voutouri C, Hadjigeorgiou AG, Papoui A, Martin JD, Stylianopoulos T.   +9 more
europepmc   +1 more source

CRCs-CAFs crosstalk-targeted nano-delivery system reprograms tumor microenvironment for oxaliplatin resistance reversing and liver metastasis inhibition in colorectal cancer. [PDF]

Bioact Mater
Liu H, Xu C, Wang P, Guo L, Yan X, Zhou R, Tang Y, Wang S, Chen J, Wang Q, Tian H.   +10 more
europepmc   +1 more source

ALYREF-Mediated Regulation of TBL1XR1 and KMT2E Synergistically Upregulates APOC1, Contributing to Oxaliplatin Resistance in Esophageal Cancer. [PDF]

Cancer Res Treat
Hu J, Liu Q, Feng B, Lu Y, Chen K.
europepmc   +1 more source

The expression of exosomal and cellular miRNAs in predicting oxaliplatin resistance in colorectal cancer cells: an in silico and in vitro study. [PDF]

BMC Cancer
Deli H, Vakili-Ghartavol Z, Asgari Y, Tavoosidana G, Eftekhar E, Ghahremani MH.   +5 more
europepmc   +1 more source

Correction: TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach. [PDF]

PLoS One
Cheraghi-Shavi T, Jalal R, Minuchehr Z, Mahjoubi F.   +3 more
europepmc   +1 more source

Oxygen vacancy-engineered bimetallic nanozymes for disrupting electron transport chain and synergistic multi-enzyme activity to reverse oxaliplatin resistance in colorectal cancer. [PDF]

J Nanobiotechnology
Zhong D, Yang X, Yang J, Luo Z, Feng Z, Ma M, Liao Y, Tang Y, Wen Y, Liu J, Hu S.   +10 more
europepmc   +1 more source

Ferroptosis-related oxaliplatin resistance in multiple cancers: Potential roles and therapeutic Implications. [PDF]

Heliyon
Zhong S, Wang Z, Yang J, Jiang D, Wang K.   +4 more
europepmc   +1 more source

METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma. [PDF]

Cell Death Differ
Jin X, Lv Y, Bie F, Duan J, Ma C, Dai M, Chen J, Lu L, Xu S, Zhou J, Li S, Bi J, Wang F, Xie D, Cai M.   +14 more
europepmc   +1 more source

Cancer-Associated Fibroblasts Enhance Oxaliplatin Resistance in Colorectal Cancer Cells via Paracrine IL-6: An In Vitro Study. [PDF]

Iran J Pharm Res
Wang J, Lu Y, Wang Z, Wei P.
europepmc   +1 more source